Fortis Therapeutics, Inc.
Fortis Therapeutics is an immuno-oncology biotech focused on developing novel antibody-drug conjugate therapies targeting CD46 for the treatment of late-stage multiple myeloma and prostate cancer. Founded on technology licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D., the company aims to deliver precision therapies that target tumor cells while sparing healthy tissue. With a strong scientific foundation and strategic partnerships, Fortis is committed to advancing cancer treatment through innovative science and rigorous partner screening.
Industries
Nr. of Employees
medium (51-250)
Fortis Therapeutics, Inc.
COI Pharmaceuticals, Avalon’s Community of Innovation, San Diego, CA
Patents
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US-12049511-B2
View Details
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US-12049511-B2
View DetailsProducts
Antibody-drug conjugate targeting CD46
A fully human antibody that binds a tumor-specific conformational epitope on CD46 and is conjugated to a potent cytotoxic payload; developed for treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma, with preclinical in vitro tumor killing and rodent efficacy.
Antibody-drug conjugate targeting CD46
A fully human antibody that binds a tumor-specific conformational epitope on CD46 and is conjugated to a potent cytotoxic payload; developed for treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma, with preclinical in vitro tumor killing and rodent efficacy.
Services
Design and execution of Phase 1 dose-escalation and expansion clinical studies for antibody-drug conjugates in metastatic cancer indications.
Design and execution of Phase 1 dose-escalation and expansion clinical studies for antibody-drug conjugates in metastatic cancer indications.
Expertise Areas
- ADC development
- Tumor-targeted antibody discovery
- Preclinical pharmacology and in vivo efficacy
- Early-phase oncology clinical development
Key Technologies
- Antibody-drug conjugates (ADC)
- Living tumor cell–based antibody selection
- Conjugation chemistry/linker technology
- In vitro cytotoxicity assays
News & Updates
On March 29, 2021, Fortis Therapeutics announced the closing of a $40 million Series A financing to fund clinical trials for FOR46, a novel antibody drug conjugate targeting CD46 for late-stage prostate cancer and multiple myeloma.
On March 29, 2021, Fortis Therapeutics announced the closing of a $40 million Series A financing to fund clinical trials for FOR46, a novel antibody drug conjugate targeting CD46 for late-stage prostate cancer and multiple myeloma.